Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/35172	Serial No. 09/251,274
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Di Rienzo et al.	
		Filing Date 02/16/99	Group 1655 ~~To Be Determined~~

MAY 24 1999 PATENT AND TRADEMARK OFFICE

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
AC	C4	Bosma, et al., "The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome," *N. Eng. J. Med.*, 333:1171-1175 (1995)
	C5	Burchell, et al.,"The UDP Glucuronosyltransferase Gene Superfamily: Suggested Nomenclature Based on Evolutionary Divergence," *DNA cell biol.*, 10:487-494 (1991)
	C6	Chen, et al., "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA," *Biotechniques.*, 6:32-638 (1988)
	C7	Clarke, et al., "The Uridine Diphosphate Glucuronosyltransferase Multigene Family: Function and Regulation," *Handbook of Experimental Pharmacology*, 112:3-43 (1994)
	C8	Coffman, et al., "Cloning and Stable Expression of a cDNA Encoding a Rat Liver UDP-Glucuronosyltransferase (UDP-Glucuronosyltransferase 1.1) That Catalyzes the Glucuronidation of Opiods and Bilirubin", Mol. Pharmacol., 47:1101-1105 (1995)
	C9	Coffman et al., "Human UGT2B7 Catalyzes Morphine Glucuronidation", *Drug Metab Dispos.*, 25:1-4 (1997)
	C10	Evans & Relling ,"Automated high-perfomance liquid chromatographic assay for the determination of 7-ethoxycoumarin and umbelliferone", *J. Chromatogr.*, 578:141-145 (19992)
	C11	Gram, et al.," Clinical relevance of genetic polymorphisms in drug oxidation", *Clinical Relevance of Genetic Polymorphisms in Drug Oxidation* (1992)
	C12	Green et al., " Expressed Human UGT1.4 Protein Catalyzes the Formation of Quaternary Ammonium-Linked Glucuronides", *Drug Metab Dispos.*, 23:299-302 (1995)
	C13	Gunn, F. H., "Hereditary Acholuric Jaundice", *J. Hered*, 29:137-139 (1938)
AC	C14	Gupta, et al., "Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea", *Cancer Res.*, 54:3723-3725 (1994)

EXAMINER	Asoke kr. Chakrabarti	DATE CONSIDERED	5/2/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/35172	Serial No. 09/251,274
INFORMATION DISCLOSURE STATEMENT		Applicant Di Rienzo et al.	
(Use several sheets if necessary)		Filing Date 02/16/99	Group 1655 To Be Determined

OIPE MAY 24 1999 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
AC	A1	5,786,344	7/28/98	Ratain, et al.	514	180	4/17/95

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
AC	B1	WO 96/01127	01/18/96	PCT	A61K	45/06		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
AC	C1	Araki, et al., "Relationship between Development of Diarrhea and the Concentration of SN-38, an Active Metabolite of CPT-11, in the Intestine and Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT-11," *Jpn J. Cancer Res*, 84:697-702 (1993)
	C2	Beutler, et al., "Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?," *PNAS USA*, 95:8170-8174 (1998)
AC	C3	Bosma, et al., "Sequence of Exons and the Flanking Regions of Human Bilirubin-UDP-Glucuronosyltransferase Gene Complex and Identification of a Genetic Mutation in a Patient with Crigler-Najjar Syndrome, Type I," *Hepatology*, 15:941-947 (1992)

EXAMINER	Arun kr. Chakraborti	DATE CONSIDERED	5/2/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 2 4 1999
PATENT & TRADEMARK OFFICE

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/35172	Serial No. 09/251,274
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Di Rienzo et al.	
		Filing Date 02/16/99	Group 1655 ~~To-Be-Determined~~

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
AC	C15	Gupta, et al., "Pharmacokinetic and Pharmacodynamic Evaluation of the Topoisomerase Inhibitor Irinotecan in Cancer Patients", *J Clin Oncol.*, 15:1502-1510 (1997)
	C16	Harding et al., "Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells", *PNAS, USA*, 85:8381-8385 (1988)
	C17	Kaneda, et al., "Metabolism and Pharmacokinetics of the Campothecin Analogue CPT-11 in the Mouse", Cancer Res, 50:1715-1720 (1990)
	C18	King et al., "The Glucuronidation of Exogenous and Endogenous Compounds by Stably Expressed Rat and Human UDP-Glucuronosyltransferase 1.1", *Arch Biochem. Biophys*, 332:92-100 (1996)
	C19	Monaghan, et al., "Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome", *Lancet*, 347:578-581 (1996)
	C20	Owens & Ritter, "Gene Structure at the Human UGT1 Locus Creates Diversity in Isozyme Structure, Substrate Specificity, and Regulation", *Progress in Nucleic Acid Research & Molecular Biology*, 51:305-338 (1995)
	C21	Purba, H. S., et al., "The metabolism of 17 α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites", *Br. J. Clin Pharmacol*, 23:447-453 (1987)
	C22	Ritter, et al., "Cloning of Two Human Liver Bilirubin UDP-glucuronosyltransferase cDNAs with Expression in COS-1 Cells", *J. Biol Chem*, 226:1043-1047 (1991)
	C23	Ritter, et al., "A Novel Complex Locus UGT1 Encodes Human Bilirubin, Phenol, and Other UDP-Glucuronosyltransferase Isozymes with Identical Carboxyl Termini", *J. Biol Chem*, 267:3257-3261 (1992)
AC	C24	Stocker, "Bilirubin Is an Antioxidant of Possible Physiological Importance", *Science*, 235:1043-1046 (1987)

EXAMINER	Arun kr. Chakrabarti	DATE CONSIDERED	5/2/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/35172	Serial No. 09/251,274
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Di Rienzo et al.	
		Filing Date 02/16/99	Group 1655 ~~To Be Determined~~

MAY 24 1999 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
AE	C25	Tucker, "Clinical Implications of Genetic Polymorphism in Drug Metabolism", *J. Pharm. Pharmacology*, 46:417-424 (1994)

EXAMINER	Arun kr. Chakrabarti	DATE CONSIDERED	5/2/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.